Aliskiren reduces portal pressure and intrahepatic resistance in biliary cirrhotic rats

Journal of the Chinese Medical Association

Volumn 75, Issue 10, 2012, Pages 501-508

  Hsieh, Yun Cheng ^a,b   Chan, Che Chang ^a,b   Lee, Kuei Chuan ^a,b   Huang, Yi Tsau ^b   Lee, Fa Yauh ^a,b   Yang, Ying Ying ^a,b   Lin, Han Chieh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Angiotensin II; Direct renin inhibitor; Intrahepatic resistance; Portal hypertension

Indexed keywords

ALISKIREN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILIARY CIRRHOSIS; BLOOD ANALYSIS; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; GENE EXPRESSION; LIVER PERFUSION; LIVER VEIN; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASODILATATION;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; FUMARATES; INFUSIONS, INTRAVENOUS; LIVER CIRCULATION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE;

EID: 84867901260     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2012.07.001     Document Type: Article

References (29)

1. Bosch J., Garcia-Pagan J.C. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000, 32:141-156.
2. Iwakiri Y., Groszmann R.J. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007, 46:927-934.
3. Lubel J.S., Herath C.B., Burrell L.M., Angus P.W. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol 2008, 23:1327-1338.
4. Herath C.B., Warner F.J., Lubel J.S., Dean R.G., Jia Z., Lew R.A., et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007, 47:387-395.
5. Paizis G., Cooper M.E., Schembri J.M., Tikellis C., Burrell L.M., Angus P.W. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002, 123:1667-1676.
6. Ballet F., Chretien Y., Rey C., Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 1988, 244:283-289.
7. Arroyo V., Bosch J., Mauri M., Ribera F., Navarro-Lopez F., Rodes J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981, 11:221-229.
8. Schneider A.W., Kalk J.F., Klein C.P. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999, 29:334-339.
9. Vollmar B., Menger M.D. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009, 89:1269-1339.
10. Gradman A.H., Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008, 51:519-528.
11. Wood J.M., Maibaum J., Rahuel J., Grutter M.G., Cohen N.C., Rasetti V., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698-705.
12. Nussberger J., Wuerzner G., Jensen C., Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1-E8.
13. Fisher N.D., Jan Danser A.H., Nussberger J., Dole W.P., Hollenberg N.K. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008, 117:3199-3205.
14. Lee KC, Yang YY, Huang YT, Lee FY, Hou MC, Lin HC, et al. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. Clin Sci (Lond) 2010;119:45-55.
15. Wood J.M., Schnell C.R., Cumin F., Menard J., Webb R.L. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005, 23:417-426.
16. Danser A.H. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?. Hypertens Res 2010, 33:4-10.
17. Yang Y.Y., Lin H.C., Huang Y.T., Lee T.Y., Hou M.C., Lee F.Y., et al. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J Hepatol 2002, 36:600-606.
18. Tandon P., Abraldes J.G., Berzigotti A., Garcia-Pagan J.C., Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol 2010, 53:273-282.
19. Vlachogiannakos J., Tang A.K., Patch D., Burroughs A.K. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001, 49:303-308.
20. Baik S.K., Park D.H., Kim M.Y., Choi Y.J., Kim H.S., Lee D.K., et al. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. J Gastroenterol 2003, 38:1150-1154.
21. Chiang H.T., Cheng J.S., Lin M., Tseng W.S., Chang J.M., Lai K.H. Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol 1995, 10:256-260.
22. Tripathi D., Therapondos G., Lui H.F., Johnston N., Webb D.J., Hayes P.C. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol 2004, 99:390-394.
23. Schepke M., Werner E., Biecker E., Schiedermaier P., Heller J., Neef M., et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001, 121:389-395.
24. Eriksson L.S., Kagedal B., Wahren J. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. Am J Med 1984, 76:66-70.
25. Chang C.C., Lee W.S., Huang H.C., Lee F.Y., Wang S.S., Lin H.C., et al. Aliskiren reduces portal pressure in portal hypertensive rats. Eur J Clin Invest 2011, 42:526-533.
26. Chang C.C., Huang H.C., Lee W.S., Wang S.S., Lee F.Y., Lin H.C., et al. Aliskiren reduces portal pressure in cirrhotic rats. Liver Int 2012, 32:692-693.
27. Sun C.Y., Cherng W.J., Jian H.Z., Hsu H.H., Wu I.W., Hsu H.J., et al. Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury-beyond the direct renin inhibition. Hypertens Res 2012, 35:304-311.
28. Koka V., Huang X.R., Chung A.C., Wang W., Truong L.D., Lan H.Y. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008, 172:1174-1183.
29. Bataller R., Sancho-Bru P., Gines P., Lora J.M., Al-Garawi A., Sole M., et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003, 125:117-125.